Cargando…

WT1 facilitates the self-renewal of leukemia-initiating cells through the upregulation of BCL2L2: WT1-BCL2L2 axis as a new acute myeloid leukemia therapy target

BACKGROUND: Overexpression of Wilms’ tumor-1 (WT1) transcription factor facilitates proliferation in acute myeloid leukemia (AML). However, whether WT1 is enriched in the leukemia-initiating cells (LICs) and leukemia stem cells (LSCs) and facilitates the self-renewal of LSCs remains poorly understoo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhou, Bin, Jin, Xianghong, Jin, Weiwei, Huang, Xingzhou, Wu, Yanfei, Li, Haiying, Zhu, Weijian, Qin, Xiaoyi, Ye, Haige, Gao, Shenmeng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7313134/ https://www.ncbi.nlm.nih.gov/pubmed/32580769 http://dx.doi.org/10.1186/s12967-020-02384-y

Ejemplares similares

DNA hypermethylation-induced miR-182 silence targets BCL2 and HOXA9 to facilitate the self-renewal of leukemia stem cell, accelerate acute myeloid leukemia progression, and determine the sensitivity of BCL2 inhibitor venetoclax
por: Ye, Sisi, et al.
Publicado: (2023)

WT1 peptide analogue WT1-126Y enhances leukemia lysis
por: Alqudaihi, Ghofran, et al.
Publicado: (2014)

Blocking the binding of WT1 to bcl-2 promoter by G-quadruplex ligand SYUIQ-FM05
por: Xiong, Yun-Xia, et al.
Publicado: (2016)

Tumor suppressor function of WT1 in acute promyelocytic leukemia
por: Christopher, Matthew J., et al.
Publicado: (2021)

WT1 Gene Mutations, rs16754 Variant, and WT1 Overexpression as Prognostic Factors in Acute Myeloid Leukemia Patients
por: Koczkodaj, Dorota, et al.
Publicado: (2022)

RBP2 Promotes Adult Acute Lymphoblastic Leukemia by Upregulating BCL2
por: Wang, Xiaoming, et al.
Publicado: (2016)

Novel WT1 Target Genes: IL-2, IL-2RB, and IL-2RG Discovered during WT1 Silencing Using Lentiviral-Based RNAi in Myeloid Leukemia Cells
por: Dejjuy, Duangnapa, et al.
Publicado: (2020)

Targeting miR‐193a‐AML1‐ETO‐β‐catenin axis by melatonin suppresses the self‐renewal of leukaemia stem cells in leukaemia with t (8;21) translocation
por: Zhou, Bin, et al.
Publicado: (2019)

Targeting Bcl-2 Proteins in Acute Myeloid Leukemia
por: Wei, Yunxiong, et al.
Publicado: (2020)

Deubiquitinase inhibitor degrasyn suppresses metastasis by targeting USP5‐WT1‐E‐cadherin signalling pathway in pancreatic ductal adenocarcinoma
por: Li, Jiajia, et al.
Publicado: (2019)

Bax, Bcl-2, and Bax/Bcl-2 as prognostic markers in acute myeloid leukemia: are we ready for Bcl-2-directed therapy?
por: Kulsoom, Bibi, et al.
Publicado: (2018)

Investigation of Antibacterial Properties of Corrosion-Resistant 316L Steel Alloyed with 0.2 wt.% and 0.5 wt.% Ag
por: Kaplan, Mikhail A., et al.
Publicado: (2022)

Phase 1/2 study of the WT1 peptide cancer vaccine WT4869 in patients with myelodysplastic syndrome
por: Ueda, Yasunori, et al.
Publicado: (2017)

Bioinformatic Analysis of the BCL-xL/BCL2L1 Interactome in Patients with Pancreatic Cancer
por: Magouliotis, Dimitrios E., et al.
Publicado: (2022)

Corrigendum: Targeting Bcl-2 Proteins in Acute Myeloid Leukemia
por: Wei, Yunxiong, et al.
Publicado: (2020)

TET2/IDH1/2/WT1 and NPM1 Mutations Influence the RUNX1 Expression Correlations in Acute Myeloid Leukemia
por: Pasca, Sergiu, et al.
Publicado: (2020)

Shikonin as a WT1 Inhibitor Promotes Promyeloid Leukemia Cell Differentiation
por: Guo, Zhenzhen, et al.
Publicado: (2022)

Progress in understanding the mechanisms of resistance to BCL-2 inhibitors
por: Xu, Yilan, et al.
Publicado: (2022)

WT1 peptide vaccine in Montanide in contrast to poly ICLC, is able to induce WT1-specific immune response with TCR clonal enrichment in myeloid leukemia
por: Liu, Hongtao, et al.
Publicado: (2018)

An oral WT1 protein vaccine composed of WT1-anchored, genetically engineered Bifidobacterium longum allows for intestinal immunity in mice with acute myeloid leukemia
por: Nakagawa, Natsuki, et al.
Publicado: (2022)

Clinical remission following ascorbate treatment in a case of acute myeloid leukemia with mutations in TET2 and WT1
por: Das, Andrew B., et al.
Publicado: (2019)

Venetoclax Overcomes Sorafenib Resistance in Acute Myeloid Leukemia by Targeting BCL2
por: Xu, Xi, et al.
Publicado: (2023)

Studies of Wilms’ Tumor (WT1) Gene Expression in Adult Acute Leukemias in Singapore
por: Lim, Che Kang, et al.
Publicado: (2007)

Prognostic Impact of WT-1 Gene Expression in Egyptian Children with Acute Lymphoblastic Leukemia
por: Hagag, Adel A, et al.
Publicado: (2016)

Crosstalk between b-catenin and WT1 signaling activity in acute myeloid leukemia
por: Wagstaff, Megan, et al.
Publicado: (2022)

Expression of BCL2L12and LIPOCALIN 2 in Adult Patient with Acute Myeloid Leukemia and Correlation with Clinical Response
por: khozam, Lucie G, et al.
Publicado: (2021)

BCL2L2 loss renders ‐14q renal cancer dependent on BCL2L1 that mediates resistance to tyrosine kinase inhibitors
por: Lyu, Yinfeng, et al.
Publicado: (2021)

Association of WT1 IgG antibody against WT1 peptide with prolonged survival in glioblastoma multiforme patients vaccinated with WT1 peptide
por: Oji, Yusuke, et al.
Publicado: (2016)

PB1789: WT1, HMGA2, EVI1, BAALC AND PRAME MRNA LEVELS IN PATIENTS BLOOD SAMPLES WITH ACUTE LEUKEMIA
por: Stolyar, M., et al.
Publicado: (2022)

Correction to: BCL2L2 loss renders ‐14q renal cancer dependent on BCL2L1 that mediates resistance to tyrosine kinase inhibitors
por: Lyu, Yinfeng, et al.
Publicado: (2023)

Characterization of the signal that directs Bcl-x(L), but not Bcl-2, to the mitochondrial outer membrane
por: Kaufmann, Thomas, et al.
Publicado: (2003)

Molecular interactions of Bcl-2 and Bcl-xL with mortalin: identification and functional characterization
por: Saxena, Nishant, et al.
Publicado: (2013)

Bcl-2 and Bcl-x(L) Suppress Glucose Signaling in Pancreatic β-Cells
por: Luciani, Dan S., et al.
Publicado: (2013)

WT1-AS promotes cell apoptosis in hepatocellular carcinoma through down-regulating of WT1
por: Lv, Long, et al.
Publicado: (2015)

PLK1 as a cooperating partner for BCL2-mediated antiapoptotic program in leukemia
por: Shah, Kinjal, et al.
Publicado: (2023)

Dual Inhibition of Bcl-2/Bcl-xL and XPO1 is synthetically lethal in glioblastoma model systems
por: Shang, Enyuan, et al.
Publicado: (2018)

Dual inhibition of FGFR4 and BCL-xL inhibits multi-resistant ovarian cancer with BCL2L1 gain
por: Guo, Ting, et al.
Publicado: (2021)

Bcl-2 is a better ABT-737 target than Bcl-xL or Bcl-w and only Noxa overcomes resistance mediated by Mcl-1, Bfl-1, or Bcl-B
por: Rooswinkel, R W, et al.
Publicado: (2012)

Wilms Tumor-1 (WT1) rs16754 Polymorphism and Clinical Outcome in Acute Myeloid Leukemia
por: Ramzi, Mani, et al.
Publicado: (2019)

UBQLN4 is an ATM substrate that stabilizes the anti‐apoptotic proteins BCL2A1 and BCL2L10 in mesothelioma
por: Liu, Fang, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_4cg9rj4rpiaaq8eu5bftkd6f42